DENGUE VACCINE

Introduction

Main Areas at Risk for Dengue

Incidence of Dengue in Brazil

Incidence of Dengue in Mexico: 1990 to 2016

Suspected Cases of Dengue Disease in the Philippines: 2015 to 2016

Incidence of Dengue in Malaysia: 1995 to 2016

Dengue Deaths in Malaysia: 1995 to 2016

Dengue Infection

Secondary Infection and Risk for Severe Dengue

Immunopathogenesis of Severe Dengue in Secondary Infections

Dengue: Clinical Picture

Preventing Infection

Dynamics of Circulating Serotypes in Mexico

Strategies in Place for Vector Control: A Challenge Remains

Development of the Dengue Vaccine

Phase 3 Trials of CYD-TDV Vaccine: Efficacy

CYD-TDV Vaccine: Efficacy According Baseline Serologic Status, Age and Region

Reduction in Dengue in Patients Aged 9 to 16 Years During the Efficacy Phase

Philippine Dengue Vaccine School-Based Immunization Program

Reactogenicity of CYD-TDV Vaccine

Public Immunization Program Against Dengue in Brazil

Recombinant Live Attenuated Dengue Vaccine in Licensed and/or Late-Stage Clinical Trials

WHO Position: Countries That Should Consider Introducing Dengue Vaccine

CYD-TDV Vaccine Age Indications

Changing the Vaccine Paradigm

Estimated Impact of Dengue Vaccination

Real-World Survey of Attitudes Toward Dengue Vaccination in Malaysia

Key Points From the Philippines

Key Points From Mexico

Closing Remarks

Abbreviations